摘要
目的研究探讨联合检测胃蛋白酶原PGⅠ、PGⅡ及VEGF在胃癌及癌前病变的诊断意义。方法采用化学发光法检测65例胃癌患者、40萎缩性胃炎患者、40例胃炎患者及112例健康对照者血清中胃蛋白酶原PGⅠ、PGⅡ含量,同时用ELSIA法测定患者血清中的VEGF的表达。结果采用方差分析发现PGⅠ、PGⅡ、PGⅠ/PGⅡ、VEGF在四组患者对比,差异有统计学意义(F分别为5.671、6.387、8.671、6.357,P均<0.05);根据患者资料可认为PGⅠ、PGⅡ、PGⅠ/PGⅡ、VEGF随着疾病的发生发展而升高三者联合检测其特异性为93.28%,灵敏性为88.35%,高于单项检测。结论患者血清PGⅠ、PGⅠ/PGⅡ比值、VEGF的检测对胃癌的诊断有一定的临床意义。联合检测可有效提高胃癌诊断的敏感度和特异性,可以作为胃癌的筛查手段。
Objective To study combined detection of pepsinogen PGI, PGII and VEGF in the diagnosis of gastric cancer and precancerous lesions. Methods Using chemiluminescence detection of 65 patients with gastric cancer, 40 patients with atrophic gastritis, 40 cases with gastritis patients and 112 healthy controls in serum pepsinogen PGI and PGII content, at the same time with ELSIA method the expression of VEGF in the serum. Results By using variance analysis found that PGI and PGII, PG I/PG II, VEGF between group differences in four groups of patients, obtained F were 5.671, 6.387, 8.671, 6.357, P〈0.05, there are differences between two groups. According to the patient information can be thought of PGI and PGII, PG I/PG II, VEGF rises with the development of disease and combined detection of the specificity of 93.28%, the sensitivity was 88.35%, significantly higher than that of single detection. Conlusion Patients＇ serum PG I, PG I/PG II ratio, the detection of VEGF has a certain clinical significance to the diagnosis of gastric cancer. Joint detection can effectively improve the sensitivity and specificity of diagnosis of gastric cancer, can be used as the screening of gastric cancer.
出处
《中国卫生标准管理》
2017年第2期127-129,共3页
China Health Standard Management
